Ciltacabtagene autoleucel vs Idecabtagene vicleucel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
Ciltacabtagene autoleucel
Marketed by Johnson & Johnson under a licence from Legend Biotech Corporation
NCT04181827 · Phase 3 · active, not recruiting
This was a large randomized phase 3 trial against active standard therapy, and its primary endpoint, progression-free survival, clearly favoured cilta-cel (hazard ratio 0.26, P<0.001). However, it was open-label: patients and doctors knew which treatment was given, so the evidence is rated below the top level.
Next expected readout: February 2027 · NCT04133636 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) (From randomization (Day 1) to either progressive disease or death, whichever occurred first (up to 3.9 years)): Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023). (met)
Result source: NCT04181827
Idecabtagene vicleucel
Marketed by Bristol-Myers Squibb
NCT03651128 · Phase 3 · completed
Randomized, open-label Phase 3 trial (n=386) demonstrating significant improvement in PFS vs standard regimens in relapsed/refractory multiple myeloma (NEJM 2023).
Next expected readout: May 2027 · NCT05393804 (registry estimate)
Reported efficacy
Progression-free survival (PFS): PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001) (met)
Result source: NCT03651128
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ciltacabtagene autoleucel | Idecabtagene vicleucel |
|---|---|---|
| PFS, median | —Trial running · NCT05257083 | 8.9bNCT03361748 |
| OS, median | 27.0bNCT03548207 | 28.3bNCT03361748 |
| ORR | 97.1%bNCT035482072 other results
| 74.5%bNCT03361748 |
| VGPR or better | 96.6%bNCT035482072 other results
| —Not posted · NCT03651128 |
| MRD negativity | 100%bNCT035482072 other results
| —Not posted · NCT03651128 |
PFS, median
- Ciltacabtagene autoleucel
- —Trial running · NCT05257083
- Idecabtagene vicleucel
- 8.9bNCT03361748
OS, median
- Ciltacabtagene autoleucel
- 27.0bNCT03548207
- Idecabtagene vicleucel
- 28.3bNCT03361748
ORR
- Ciltacabtagene autoleucel
- 97.1%bNCT03548207
2 other results
- 57.3% NCT05347485
- 100% NCT03548207
- Idecabtagene vicleucel
- 74.5%bNCT03361748
VGPR or better
- Ciltacabtagene autoleucel
- 96.6%bNCT03548207
2 other results
- 94.1% NCT03548207
- 100% NCT03548207
- Idecabtagene vicleucel
- —Not posted · NCT03651128
MRD negativity
- Ciltacabtagene autoleucel
- 100%bNCT03548207
2 other results
- 89.7% NCT03548207
- 75% NCT03548207
- Idecabtagene vicleucel
- —Not posted · NCT03651128
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety
Coverage. Ciltacabtagene autoleucel: 7 of 9 rows · Idecabtagene vicleucel: 8 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ciltacabtagene autoleucel Rows use multiple source trials | Idecabtagene vicleucel |
|---|---|---|
| Complete responder rate · % of participants No placebo or comparator arm | 17.1% (n=82)a,b,c NCT05347485 · Phase 2 · registry result, not featured evidence | 34.3% (n=137)a,b,c NCT03361748 · Phase 2 |
| Duration of Response time to event · months No placebo or comparator arm | NA monthsd,e,a,b,c NCT03548207 · Phase 1/2 | 11.04 monthse,a,b,c NCT03361748 · Phase 2 |
| ORR responder rate · % of participants No placebo or comparator arm | 100% (n=8)d,e,a,b,c NCT03548207 · Phase 1/2 show 1 more dose97.1% (n=68) NCT03548207 · Phase 1/2 | 74.5% (n=137)e,a,b,c NCT03361748 · Phase 2 |
| Overall Survival time to event · months No placebo or comparator arm | NA monthsd,e,a,b,c NCT03548207 · Phase 1/2 | 28.25 monthse,a,b,c NCT03361748 · Phase 2 |
| PFS time to event · months No placebo or comparator arm | NA monthsd,e,a,b,c NCT03548207 · Phase 1/2 | 8.9 monthse,a,b,c NCT03361748 · Phase 2 |
| Dropout rate | n/a: no completion milestonef NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more resultsn/a: no completion milestonePhase 1b (US Population) NCT03548207 · Phase 1/2 n/a: no completion milestonePhase 2 (Japan Population) NCT03548207 · Phase 1/2 n/a: no completion milestonePhase 2 (US Population) NCT03548207 · Phase 1/2 n/a: no completion milestone NCT05347485 · Phase 2 · registry result, not featured evidence | 73.7%g NCT03361748 · Phase 2 show 1 more result5% NCT05032820 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —f NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more results—Phase 1b (US Population) NCT03548207 · Phase 1/2 —Phase 2 (Japan Population) NCT03548207 · Phase 1/2 —Phase 2 (US Population) NCT03548207 · Phase 1/2 — NCT05347485 · Phase 2 · registry result, not featured evidence | —g NCT03361748 · Phase 2 show 1 more result— NCT05032820 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 47.1%f NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more results37.9%Phase 1b (US Population) NCT03548207 · Phase 1/2 11.1%Phase 2 (Japan Population) NCT03548207 · Phase 1/2 61.8%Phase 2 (US Population) NCT03548207 · Phase 1/2 51.2% NCT05347485 · Phase 2 · registry result, not featured evidence | 78.8%g NCT03361748 · Phase 2 show 1 more result22.5% NCT05032820 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | f neutropenia 89.9% cytokine release syndrome 62% thrombocytopenia 54.3% NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more resultsneutropenia 80.5% anaemia 59.8% cytokine release syndrome 57.3% NCT05347485 · Phase 2 · registry result, not featured evidence | show 1 more resultlymphocyte count decreased 85% neutrophil count decreased 77.5% white blood cell decreased 72.5% NCT05032820 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eTrial phases differ: Phase 1/2 versus Phase 2.
- fPopulation comparability has not been reviewed for 4 of these studies.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ciltacabtagene autoleucel
show 3 more results
show 27 more results
show 27 more results
show 27 more results
show 7 more results
Idecabtagene vicleucel
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ciltacabtagene autoleucel's landscape · Idecabtagene vicleucel's landscape